Deerfield Management’s ADC Therapeutics ADCT Stock Holding History

Deerfield Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,390,297	Closed	-$11.5M	–	105
2022 Q3	$11.5M	Buy	+2,390,297	New	+$17.3M	0.23%	78
2020 Q4	–	Sell	-300,000	Closed	-$9.9M	–	130
2020 Q3	$9.9M	Sell	300,000 -200,000	-40%	-$8.66M	0.24%	84
2020 Q2	$23.4M	Buy	+500,000	New	+$19M	0.68%	45

Other funds holding ADCT

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deerfield Management's ADCT Position: Q4 2022 in Review

Deerfield Management sold out of ADC Therapeutics (ADCT) in Q4 2022, closing a stake of 2,390,297 shares — an estimated $11.5M sold.

Deerfield Management first reported a position in ADCT in Q2 2020 and held it in 3 quarters. The position peaked at $23.4M in Q2 2020. 60 funds tracked by Wall St. Rank hold ADCT as of Q4 2022.

Deerfield Management reported no remaining ADC Therapeutics position as of Q4 2022 after selling out during the quarter.
Deerfield Management sold 2,390,297 ADC Therapeutics shares in Q4 2022, an estimated $11.5M.
Deerfield Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 3 quarters.
Deerfield Management's ADC Therapeutics position peaked at $23.4M in Q2 2020.
60 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2022.

Based on Deerfield Management's 13F filing for Q4 2022, filed 14 Feb 2023.